Monica Gandhi, MD; Lucy Horton, MD; Jonathan Li, MD
This activity is jointly provided by Global Education Group and Integritas Communications.
This educational activity is supported by an educational grant from GlaxoSmithKline.
Monica Gandhi, MD, MPH
Professor of Medicine
Associate Division Chief (Clinical Operations/Education)
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco / San Francisco General Hospital
San Francisco, California
Lucy Horton, MD, MPH
Associate Professor of Medicine
Infectious Disease Specialist
UC San Diego Health
San Diego, California
Jonathan Li, MD, MMSc
Associate Professor of Medicine
Brigham and Women’s Hospital
Harvard Medical School
Director, Harvard/Brigham Virology Specialty Laboratory
This program is intended to educate infectious disease, internal medicine, and other clinicians involved in the management of patients with mild or moderate coronavirus disease 2019 (COVID-19) who are at risk for clinical progression.
As the COVID-19 pandemic continues to be an overwhelming public health concern around the world, there is also rapid progress in both treatment and prevention. Multiple anti-SARS-CoV-2 monoclonal antibodies (mAbs) have gained Emergency Use Authorization (EUA) from the US Food and Drug Administration, though clinicians and patients alike have questions about safety, efficacy, eligibility, access, and implementation. A panel of experts will present data on and discuss current evidence and regulatory status for these anti-SARS-CoV-2 mAbs, updates to National Institutes of Health guidelines on patient identification and stratification, implementation, and strategies to reduce health care disparities. Patient-clinician interactions will be included to provide examples of optimal communication.
After completing the activity, participants will be better prepared to:
- Discuss the clinical profiles and trial data for current and emerging anti-SARS-CoV-2 mAbs
- Assess patients with COVID-19 who are at high risk for clinical progression, hospitalization, and other poor outcomes
- Manage patients with COVID-19 who qualify for anti-SARS-CoV-2 monoclonal antibody therapy based on current guidelines from the US Food and Drug Administration
- Address barriers to the use of anti-SARS-CoV-2 monoclonal antibody therapies, including patient reluctance and healthcare disparities
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.1 hour(s) of pharmacology).
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Monica Gandhi, MD, MPH Nothing to disclose
Lucy Horton, MD, MPH Nothing to disclose
Jonathan Li, MD, MMSc Consulting Fee: AbbVie
The planners and managers have the following relevant financial relationships with ineligible companies:
Kristin Delisi, NP: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Kim Rodriguez: Nothing to disclose
Gena Dolson, MS: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions to Receive Credit
In order to received credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Review the activity content.
- Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation to receive credit.
Term of Offering
This actiivty was released on October 15, 2021, and is valid for one year. Requests for credit must be made no later than October 15, 2022.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 1.00
credit type CME/CE
An Update on Monoclonal Antibody Therapies